STM JOURNALS

Research & Reviews: A Journal of
Pharmacology

https://journals.stmjournals.com/rrjop

ISSN: 2230-9861 (Online)
ISSN: 2349-1299 (Print)
Volume 16, Issue 1, 2026
January–April
DOI (Journal): 10.37591/RRJoP

Research RRJOP

Cancer Chemotherapy-Induced Cachexia: Bridging Mechanisms, Management, And Future Therapies

Sneha Sanjay Pawar[1,*], Ansari Wasil Ahmed Kafeel[2]

Abstract

Involuntary weight loss, skeletal muscle atrophy, adipose tissue depletion, anorexia, and systemic inflammation are all symptoms of chemotherapy-induced cachexia, a complex illness. Although it is common, it remains poorly understood and is often referred to as an "orphan disease." This study covers the epidemiology, pathophysiology, clinical symptoms, diagnosis, treatment, and emerging treatment options for chemotherapy-induced cachexia. To comprehend the causes, clinical results, and therapeutic approaches, a literature-based synthesis of recent clinical and preclinical research, as well as professional guidelines, was carried out. By causing gastrointestinal toxicity, systemic inflammation, metabolic dysregulation, mitochondrial dysfunction, and neuroendocrine changes, chemotherapy causes cachexia, which leads to a gradual loss of muscle and fat. Symptoms of cachexia include reduced chemotherapeutic tolerance, diminished functional ability, poor quality of life, and shortened survival. Treatment of cachexia includes pharmacological medications, exercise programs, multimodal techniques, and dietary assistance, which are the mainstays of current care. Emerging medicines that target pathways of inflammation, anabolic signaling, metabolic regulation, and gut microbiome show promise but require further clinical testing. Cachexia brought on by chemotherapy is a serious but often ignored symptom. To enhance treatment results, functional status, and survival, early detection, uniform diagnostic standards, and customized multimodal therapies are crucial. Additional research is required to develop targeted therapies and provide meaningful therapeutic guidelines.

Keywords: Cancer, chemotherapy-induced cachexia, inflammation, metabolic dysregulation, multimodal therapy, muscle wasting, orphan disease

INTRODUCTION

Cancer is a leading global cause of death and poses significant challenges due to its complex nature and treatment toxicity. Chemotherapy remains a primary treatment for many cancers, effective in targeting rapidly dividing cancer cells, but it can cause severe side effects that impact patients' nutrition and metabolism, with chemotherapy-induced cachexia (CIC) being a particularly debilitating and often overlooked consequence [1]. Cachexia differs from simple starvation due to metabolic abnormalities, hormonal imbalances, and systemic inflammation, resulting in irreversible muscle mass loss and reduced functional capacity. Inflammatory cytokines like TNF-α and IL-6 are overexpressed, initiating proteolytic and lipolytic pathways that lead to ongoing muscle and adipose tissue degradation [2]. These metabolic changes are largely irreversible with standard nutritional therapy, indicating the condition's severity. Cachexia contributes to 20–30% of cancer-related deaths and impacts 50–80% of patients with advanced cancers [3]. Chemotherapy-induced cachexia (CIC), although less studied than cancer-associated cachexia, emerges from the toxic effects of chemotherapeutic agents like cisplatin,

***Author for Correspondence**
Sneha SanjayPawar
E-mail: snehapawar0270@gmail.com

[1]Professor, Department of Pharmacy, SVSs Dadasaheb Rawal Pharmacy College, Dondaicha, Tal-Shindkheda, Dist-Dhule, Maharashtra, India
[2]Professor, Department of Pharmacology, Affiliated to Dr. Babasaheb Ambedkar Technological University, Lonere, Raigad, Maharashtra, India

Received Date: November 23, 2025
Accepted Date: January 23, 2026
Published Date: January 24, 2026

Citation: Sneha Sanjay Pawar, Ansari Wasil Ahmed Kafeel. Cancer Chemotherapy-Induced Cachexia: Bridging Mechanisms, Management, And Future Therapies. Research & Reviews: A Journal of Pharmacology. 2026; 16(1): 17–26p.

doxorubicin, and irinotecan [4, 5]. These drugs lead to oxidative stress, mitochondrial dysfunction, gastrointestinal damage, and systemic inflammation, activating catabolic pathways in skeletal muscle, which increases protein degradation and suppresses protein synthesis. Consequently, patients may experience muscle mass loss regardless of tumor status, indicating that CIC can occur independently of cancer progression.

Chemotherapy-induced cachexia at the molecular level is characterized by the activation of the NF-κB and STAT3 signaling pathways, which increase the expression of muscle-specific E3 ubiquitin ligases like MuRF1 and Atrogin-1, leading to protein breakdown in skeletal muscle [6]. Inhibition of regulatory proteins like PGC-1α and NRF1 suppresses mitochondrial biogenesis, leading to decreased mitochondrial activity and energy production. This imbalance fosters oxidative stress and muscle fatigue, which play a role in the progression of cachexia [7]. Chronic Inflammatory Cachexia (CIC) leads to severe tiredness, weight loss, and decreased activity tolerance, negatively impacting quality of life. It reduces lean body mass, affecting the pharmacokinetics of chemotherapy, increasing toxicity, and the risk of organ damage, which may result in treatment delays, dosage reductions, or termination, ultimately threatening therapeutic outcomes and survival rates [8].

Chemotherapy-induced cachexia is challenging to diagnose early due to its overlap with tumor symptoms. Clinically significant weight loss is defined as over 5% in six months or 2% in individuals with a BMI below 20 kg/m². Important biochemical indicators include elevated C-reactive protein (CRP), IL-6, TNF-α, and low levels of serum albumin, pre-albumin, and hemoglobin. Advanced diagnostic tools like CT and DEXA imaging can assess skeletal muscle index and sarcopenia, offering better insight into cachexia's progression [2, 3]. Management of chemotherapy-induced cachexia necessitates a multimodal approach that addresses energy balance, muscle preservation, and inflammation reduction. Essential nutritional support involves high-protein diets, omega-3 supplementation, and vital micronutrients. However, due to ongoing inflammation and hormonal imbalances, nutrition alone may not suffice. Consequently, pharmacological interventions such as progestins, ghrelin receptor agonists, and selective androgen receptor modulators (SARMs) are explored to enhance appetite, promote muscle growth, and reduce catabolism [3, 4].

Exercise therapy and physiotherapy are crucial in managing cachexia, aiding in muscle strength preservation, physical function improvement, and anabolic signaling stimulation. Additionally, psychological support and counseling are vital due to the associated risks of depression, anxiety, and social withdrawal resulting from changes in physical appearance and fatigue [8].

EPIDEMIOLOGY & CLINICAL BURDEN

There are significant geographical, gender, and survival differences in cachexia occurrence. Cachexia is more common in low- and middle-income nations, where hunger and a lack of supportive care worsen chemotherapy-induced wasting, according to studies. There have also been reports of gender-based differences: male patients lose lean body mass more quickly than female patients, possibly due to less estrogen-mediated protection against catabolism. Furthermore, as cancer survival rates have improved, a new concern has emerged: late-onset cachexia in long-term survivors. Survivors of breast, colorectal, and hematologic malignancies may develop sarcopenia and metabolic changes years after treatment completion, showing that chemotherapy-induced cachexia is a continuous survivability risk rather than an acute therapeutic consequence [9].

PATHOPHYSIOLOGY OF CHEMOTHERAPY-INDUCED CACHEXIA

- *Dysregulation of Metabolism:* Chemotherapy promotes muscle protein breakdown and adipose tissue lipolysis. The ubiquity-proteasome system and autophagy pathways are unregulated in skeletal muscle, leading to rapid muscle atrophy. Chemotherapy also increases resting energy expenditure, partially owing to mitochondrial uncoupling and systemic inflammation, resulting in a negative energy balance that exacerbates weight loss [8].

- *Microbiota in the Gut:* Recent data indicate that chemotherapy-induced alterations in the gut microbiota may influence systemic inflammation, energy metabolism, and muscle catabolism [10]. Anorexia and metabolic stress can be made worse by symbiosis, suggesting a possible area for management.
- *Epigenetic Regulation:* Chemotherapy-induced cachexia is increasingly linked to non-coding RNA's (mRNAs), particularly microRNA (miR-206, miR-21, and miR-486). These regulate the breakdown of proteins through mechanisms including autophagy and the ubiquity-proteasome complex. Aberrant expression of these mRNAs results in increased muscle proteolysis and poor regeneration, pointing to potential markers and therapeutic targets [11].
- *Impairment of Mitochondrial Biogenesis:* Chemotherapy impairs mitochondrial biogenesis by damaging DNA and suppressing regulators such as PGC-1α and NRF1, resulting in reduced replication and ATP generation. This increases ROS production, exacerbating oxidative stress, muscular fatigue, and wasting [12].
- *Immunological Dysregulation:* Chemotherapy disturbs immunological homeostasis and produces pro-inflammatory cytokines. Myeloid-derived suppressor cells (MDSCs) expand in response to chemotherapy, impairing immunological function, inducing systemic inflammation, and enhancing catabolism [13] (Figure 1).

CLINICAL FEATURES

The multifactorial illness known as chemotherapy-induced cachexia (CIC) is typified by a persistent loss of skeletal muscle mass, with or without a loss of fat mass, that is not entirely reversible with traditional nutritional assistance. The range of symptoms is wide, from minor weight loss to severe treatment intolerance and functional impairment.

- *Sarcopenia, or Muscle Wasting:* Muscular weakness, reduced grip strength, and muscular atrophy are all frequent. Patients complain of fatigue, difficulty moving about, difficulty performing daily duties, and trouble inhaling due to weak diaphragms [14].
- *Metabolic and Systemic Effects:* A rise in TNF, IL-6, and CRP is associated with chronic systemic inflammation.
  - A decrease in caloric intake but an increase in REE (resting energy expenditure).
  - Endocrine alterations include reduced ghrelin and testosterone, elevated cortisol, and insulin resistance.
  - These help to promote catabolism and muscular protein breakdown.
- *Functional Decline and Quality of Life:* Patients report feeling weak, exhausted, losing their independence, and having a lower tolerance for physical activity.
  - The ability to complete chemotherapy cycles is limited because of the significant decline in functional status.
  - Cachexia is substantially associated with a worse quality of life and more psychological discomfort [15].
- *Neurocognitive Decline:* Inflammation, mitochondrial dysfunction, and reduced nutritional availability cause "chemo brain," which is characterized by memory issues, poor focus, and mental tiredness and is now recognized as a systemic effect of cachexia [16].
- *Psycho-Logical Distress:* Losing weight and losing muscle changes how people feel about their bodies and their independence, which exacerbates anxiety, despair, and poor treatment compliance. Psychosocial factors are frequently overlooked in cancer therapy, although they have a significant impact on quality of life [17].
- *Sarcopenia Obesity:* Patients may have a normal/high BMI but have diminished muscle mass, which is hidden by fat. These individuals are more likely to experience chemotherapy toxicity because medication distribution is dependent on lean tissue. Without muscle assessment (CT/DEXA), diagnosis is frequently delayed [18].

DIAGNOSIS OF CHEMOTHERAPY-INDUCED CACHEXIA

Chemotherapy-induced cachexia (CIC) is especially difficult to diagnose since it overlaps with cancer-associated cachexia and is complicated by chemotherapy-related side symptoms such as

anorexia, nausea, and gastrointestinal damage. Cancer cachexia itself has a widely recognized definition, but there are no widely agreed-upon particular diagnostic standards for CIC, which has led to its designation as an "orphan disease." Nonetheless, numerous clinical, anthropometric, imaging, biochemical, and functional characteristics can be used to make the diagnosis.



Figure 1. Systematic flowchart of pathophysiology pathways in chemotherapy-induced cacexia.

CONSENSUS DEFINITIONS RELEVANT TO DIAGNOSIS

According to the Most Often Used Definition, Cachexia is [1]

Weight loss >5% in the last 6 months (excluding simple hunger), OR Patients with BMI <20 kg/m² or sarcopenia may have weight reduction of more than 2%. In the context of chemotherapy, weight loss often occurs temporally in relation to treatment cycles and is associated with chemotherapy-induced toxicities such as mucositis, nausea, and diarrhea, distinguishing it from tumor-driven cachexia.

Biochemical and Molecular Biomarkers

- Inflammatory markers such as CRP, IL-6, TNF, and fibrinogen indicate systemic inflammation.
- Low serum albumin, pre albumin, transferring, and total cholesterol levels indicate malnutrition and a bad prognosis.
- Hormonal Changes: It is common to have hypogonadism, insulin resistance, hypercortisolaemia, and reduced IGF-1.
- Emerging Biomarkers: Myostatin, activin A, growth differentiation factor-15 (GDF-15), and circulating microRNA are being studied for early diagnosis.

Differential Diagnosis

- Cancer-related cachexia (disease-driven, unaffected by therapy).
- Simple malnutrition, as opposed to cachexia, is reversible with proper nutrition.
- Anorexia nervosa or depression-induced weight loss.
- Nausea and vomiting brought on by chemotherapy alone, which could result in temporary weight loss without the metabolic changes associated with cachexia.

AI-Based Imaging

Applying machine learning algorithms to CT/MRI images allows for automated, precise, and quick muscle volume assessment, facilitating early diagnosis in routine oncology [19].

New Biomarkers

GDF-15 and activin A may indicate cachexia before clinical weight loss. These biomarkers might aid in risk assessment and intervention customization [20].

Wearable Devices

Like activity trackers and digital grip strength monitors are becoming popular for tracking cachexia development and delivering real-time data beyond treatment appointments [21].

IMPACT ON THE RESULTS OF CANCER TREATMENT

Cachexia brought on by chemotherapy has a major impact on the effectiveness of cancer treatments and the prognosis of patients. The syndrome not only impairs tolerance to cytotoxic treatments, but it also contributes to higher treatment-related toxicity, low response rates, and worse overall survival [3].

- *Reduced Chemotherapy Tolerance:* Patients with cachexia are more likely to require dosage reductions, treatment delays, or early termination of chemotherapy due to an increased sensitivity to side effects such as neutropenia, gastrointestinal toxicity, and exhaustion [6]. This frequently disrupts the targeted therapy regimen and reduces overall treatment effectiveness.
- *Increased toxicity and complications:* Cachexia brought on by chemotherapy is linked to increased drug toxicity, which includes organ malfunction, neuropathy, and mucositis. Reduced lean body mass can cause altered pharmacokinetics, resulting in increased medication plasma concentrations, worsening adverse effects and requiring hospitalization [4].
- *Poor Prognosis and Survival:* Numerous studies have shown that cachexia causes cancer patients to have a lower chance of survival. Regardless of tumor burden, cachexia impairs immune competence, reduces functional reserve, and increases morbidity and mortality [5].
- *Quality of Life Impairment:* Beyond survival, cachexia significantly lowers quality of life by reducing physical function, independence, and psychosocial well-being. Weakness, fatigue, and

functional decline make it harder to engage in daily activities and social interactions, which adds to the overall burden of disease [2].

- *Economic and Healthcare Burden:* Patients frequently need more supportive care, frequent hospital stays, and additional interventions to manage complications, which raises healthcare expenses and resource utilization [8].

CURRENT MANAGEMENT APPROACHES FOR CHEMOTHERAPY-INDUCED CACHEXIA

Principles of Management

The objectives of CIC management are to

- Stop more weight and muscle loss,
- Maintain or enhance physical function and performance status,
- Maximize resistance to anticancer treatment, and
- Enhance life quality. Because CIC shares pathophysiological drivers with cancer cachexia (inflammation, proteolysis, lipolysis, mitochondrial dysfunction) but is temporally associated with cytotoxic therapy, interventions are frequently directed at both symptomatic problems (nausea, mucositis, anorexia) and biochemical drivers (inflammation, anabolic deficit) [1, 3].

Nutritional Interventions

Nutrition is fundamental; addressing protein and calorie deficiencies lessens the substrate constraint for muscle protein synthesis and lessens the role that malnutrition plays in immune system impairment and tiredness. However, because cachexia is caused by metabolic dysfunction, nutritional treatment is required but not often adequate [2, 3].

Components and Evidence

- *Dietary Counseling and Individualized Plans:* For specialized, pleasant, high-protein, energy-dense programs, it is advised to see a clinical dietitian as soon as possible.
- *Oral Nutritional Supplements (ONS):* High-protein, high-energy ONS with additional micronutrients are frequently used to supplement intake; studies demonstrate enhanced intake and some weight gain but inconsistent effects on lean mass and function when taken alone.
- *Omega-3 Fatty Acids (EPA/DHA):* EPA supplementation has been linked to slower weight loss and lower inflammatory markers in numerous short trials and meta-analyzes; however, the benefits are limited and vary between studies.
- *Enteral and Parenteral Nutrition:* is used in cases of severe Gl toxicity or blockage when oral intake is difficult. Parenteral feeding can help sustain caloric intake, but it does not address cytokine-driven catabolism and poses infection/metabolic concerns. Timing is critical-support is most effective if initiated before permanent functional deterioration.
- *Limitations:* Nutritional therapies seldom recover lost muscle mass in isolation because inflammation and proteolysis persist until other causes are addressed [2, 7].

PHARMACOLOGICAL THERAPIES

Appetite Stimulants and Progestins

Megestrol acetate (progestin) is the most extensively researched treatment for cancer-related anorexia and cachexia. It increases hunger and body weight (mostly fat/water), although improvements in lean mass and function are variable; hazards include thromboembolism and adrenal suppression [3]. Medroxyprogesterone acetate has similar appetite advantages but has comparable limits.

Ghrelin and Its Mimetic Effects

Ghrelin receptor agonists have the ability to increase anabolism and promote appetite. Although benefits in handgrip strength or physical function were less consistent, agents like anamorelin have been demonstrated in randomized trials (like the ROMANA studies) to enhance lean body mass and hunger; regulatory approval and availability varies by location. Although they need more function and survival data, Ghrelin analogs show promise [2, 3].

Anabolic Therapies and SARMs

Testosterone replacement therapy and selective androgen receptor modulators (SARMs) improve lean mass, but their safety in cancer (possible activation of androgen-sensitive cancers) and long-term results remain concerns. To give anabolic benefits with less androgenic adverse effects, SARMs are being studied [2].

SUPPORTIVE AND PALLIATIVE CARE METHODS

Symptom management (nausea, mucositis, discomfort, sadness) boosts appetite and capacity to participate in nutrition/exercise programs.

Psychosocial assistance tackles anxiety, sadness, and caregiver strain, all of which influence intake and adherence.

When cachexia worsens despite treatment, advance care planning and goal-of-care talks are critical. Integration with palliative care improves symptom alleviation and overall quality of life [8].

- *Digital Health Tools:* Remote therapies delivered through applications increase adherence to nutrition and exercise programs, minimizing hospital visits and boosting outcomes [22].
- *Immunonutrition:* Arginine, omega-3 fatty acid, and nucleotide-enriched formulas lower systemic inflammation, boost immunity, and maintain muscle mass [23].
- *Psychosocial Support:* Structured psychotherapy, mindfulness training, and caregiver participation can reduce emotional and behavioral obstacles to eating and exercise, thereby enhancing cachexia outcomes [24].
- *Precision Medicine:* Biomarker-driven treatment, such as anti-IL-6 antibodies for high IL-6 patients, is the future of managing cachexia [25].

EMERGING THERAPIES & RESEARCH DIRECTIONS

Gut Microbiota Modulation

- Recent research reveals that chemotherapy-induced dysbiosis contributes to systemic inflammation and metabolic imbalance.
- Probiotics, prebiotics, and nutritional treatments that target gut microbiota may slow cachexia development [10].

Exercise and Multimodal Innovations

- The combination of exercise, diet, and pharmaceutical therapies continues to show promise for preserving muscle mass and functional performance.
- Digital health technologies and remote monitoring can customize intervention programs, leading to better adherence and outcomes [8].

Strategies Based on CRISPR

A preclinical study employing CRISPR-Cas9 editing of the myostatin gene has revealed that muscle atrophy can be reversed, opening up a novel treatment option [26].

Microbiome-Targeted Therapy

Dysbiosis is increasingly being related to cachexia. Probiotics, prebiotics, and fecal microbiota transplantation (FMT) are promising interventions for lowering systemic inflammation [27].

Nanomedicine

By reducing toxicity, nanoparticles allow for the targeted administration of anabolic and antioxidant substances straight to muscle tissues [28].

Combination Methods

Exercise, ghrelin mimetic, and diet work better together as a synergistic intervention than as a single therapy, underscoring the necessity of multimodal approaches [29].

CHALLENGES OF CANCER CHEMOTHERAPY-INDUCED CACHEXIA (CCIC):

- *Lack of Standardized Diagnostic Criteria:* There are no universal criteria or staging approaches for chemotherapy-induced cachexia.
  - Variability in early identification, risk assessment, and patient selection occurs in clinical trials [30].
- *Neglecting Research and Excluding Clinical Trials:* Patients with cachectic symptoms are frequently disqualified from studies because of their subpar performance.
  - This results in a dearth of high-quality evidence and sluggish medication development [31].
- *Psychosocial and Quality of Life BURDEN:* Cachexia causes tiredness, despair, social stigma, and decreased independence.
  - These characteristics are infrequently addressed in conventional cancer care, affecting the overall prognosis [32].
- *Paediatric Cachexia:* Chemotherapy-induced cachexia among kids is linked with growth retardation and developmental disability, which presents specific therapeutic issues [33].
- *LMICs:* Lack of resources in low- and middle-income nations impairs access to multimodal treatment and delays diagnosis, which lowers survival rates [34].
- *Clinical Trial Barriers:* Cachectic sufferers' poor performance typically prevents high-quality data gathering and slows treatment development [35].

FUTURE DIRECTION

Cachexia brought on by chemotherapy (CIC) is a dangerous but occasionally disregarded side effect of cancer treatment. Instead of addressing symptoms, it advocates for early, mechanism-based therapy. Early detection and risk stratification are crucial most treatments occur after severe muscle loss. Metabolomics, inflammatory profiling, biomarkers such as GDF-15 and activin A, as well as imaging assessments, may be useful in finding CIC more promptly. Furthermore, utilizing AI and big data technologies could boost prediction models for identifying individuals at high risk of muscle wasting before clinical symptoms become obvious.

Future therapeutic strategies will focus on personalized multimodal approaches that combine nutritional support, exercise, psychosocial care, and pharmacological therapies. Treatments will be tailored based on biomarkers, utilizing options such as IL-6 antagonists for high inflammatory profiles and ghrelin mimetics for appetite suppression. Advances in molecularly targeted therapies include myostatin/activin inhibitors, selective androgen receptor modulators (SARMs), and mitochondria-protective agents. Innovative technologies like CRISPR-Cas9 for gene editing and nanomedicine for targeted drug delivery to muscle tissues represent emerging frontiers in this field.

The gut microbiome plays a significant role in health, particularly in chemotherapy-induced dysbiosis, which exacerbates inflammation and nutrient metabolism issues. Interventions like probiotics, prebiotics, and fecal microbiota transplantation (FMT) could reduce cachexia progression. Additionally, digital health technologies such as telemedicine and wearable devices are anticipated to be crucial for monitoring patient activity and adherence to treatments. Integrating cachexia into oncology guidelines is essential, similar to how pain and nausea are monitored. Organizations like ESMO, ESPEN, and EORTC are developing harmonized diagnostic criteria and standardized outcome measures to facilitate large-scale trials in cancer care.

Finally, the future of CIC management relies on early detection, personalized biomarker guidance, multimodal therapy, and innovative interventions. Strengthening international collaborations and integrating cachexia care into standard oncology practice can transform CIC from an "orphan disease" into a preventable and manageable condition, enhancing survival, treatment tolerance, and quality of life for cancer patients.

CONCLUSION

Cancer chemotherapy-induced cachexia (CCIC) is a complex and burdensome condition characterized by substantial body weight loss, muscular wasting, and metabolic dysregulation in cancer

patients receiving chemotherapy. Despite breakthroughs in oncologic therapy, CCIC remains mostly unknown and undertreated, earning it the designation of an "orphan disease." The etiology of this syndrome is based on the intricate interactions between anorexia, altered energy metabolism, systemic inflammation brought on by chemotherapy, and direct cytotoxic effects on muscle and adipose tissue. CCIC not only reduces patients' quality of life, but it also has a detrimental influence on treatment efficacy, chemotherapeutic regimen tolerance, and overall survival rates. The majority of current therapeutic options are supportive and include physical rehabilitation, pharmaceutical medications that target inflammation and catabolism, and dietary therapies. However, because the illness is complex, these techniques are not very effective. To successfully prevent or reverse CCIC, focused research is desperately needed to find molecular processes, predictive biomarkers, and new treatment targets. Recognizing CCIC as a unique clinical entity and incorporating early screening techniques into oncological treatment are critical steps toward reducing its impact. Finally, a multidisciplinary strategy that includes oncology, nutrition, pharmacology, and rehabilitation is critical to improve patient outcomes and treat this overlooked side effect of cancer therapy.

Acknowledgements

The authors are thankful to the Principal and Head of the Department of SVS's Dadasaheb Rawal Pharmacy College, Dondaicha, for providing all facilities to complete the present study successfully.

REFERENCES

1. Fearon K, Strasser F, Anker SD, Bosaeus L, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95.
2. Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol. 2018;34:61–71.
3. Baracos VE, Martin L, Korc M, Guttridge DC. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4(1):17105.
4. Damrauer JS, Stadler ME, Acharyya S, Baldwin AS, Couch ME. Chemotherapy-induced muscle wasting: association with NF-κB and muscle function. J Clin Invest. 2018;128(10):4553–68.
5. Barreto R, Waning DL, Gao H, Lio Y, Bonetto A. Chemotherapy-related cachexia is associated with mitochondrial dysfunction and oxidative stress. Cancer Lett. 2016;370(2):177–89.
6. Rier HN, Jager A, Sleijfer S. The prevalence and clinical relevance of cachexia in cancer patients receiving chemotherapy: a prospective cohort study. Support Care Cancer. 2018;26(5):1531–39.
7. Arends J, Strasser F, Gonella S, Ravasco P, Chasen M, Baldwin C, et al. Cancer cachexia in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2021;32(12):1637–53.
8. Muscaritoli M, Bertz H, Bachmann P, Baracos V, et al. Cancer cachexia: ESMO clinical practice guidelines update. Clin Nutr. 2021;40(7):4789–800.
9. Martin L, Birdsell L. Global patterns and sex-based differences in cancer cachexia prevalence. J Cachexia Sarcopenia Muscle. 2023;14(4):1955–68.
10. Bindels LB, Neyrinck AM, Claus SP. Gut microbiota-derived metabolites in cancer cachexia: mechanisms and therapeutic opportunities. Curr Opin Clin Nutr Metab Care. 2018;21(5):375–81.
11. Zhang Y, Wang J, Yu X, Zhao H, Lai S. Epigenetic regulation in cancer cachexia. Front Cell Dev Biol. 2022;10:862145.
12. Heden TD, Cameron RB, Peterson YK, Beeson CC. Mitochondrial biogenesis impairment. Cancers (Basel). 2023;15(3):812.
13. Roy A, Banerjee S. Immune dysregulation in cachexia. Front Immunol. 2022;13:902176.
14. Prado CMM, Sawyer MB, Ghosh S, Brown EA, Earthman I, Baracos VE. Central tenet of cancer cachexia therapy: targeting lean tissue. Clin Cancer Res. 2012;18(21):5716–24.
15. Muscaritoli M, Arends J, Bachmann P, Bozzetti F, Kaasa S, Barthelemy N, et al. ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr. 2021;40(5):2898–913.
16. McGovern J, Stone P. Cachexia, fatigue, and cognitive impairment. Support Care Cancer. 2023;31(6):3201–12.
17. Dutta S, Ghoshal S. Psychological aspects of cachexia. Psychooncology. 2022;31(11):1905–14.
18. Yoshida T, Fukuda Y. Sarcopenic obesity in chemotherapy. Nutrients. 2023;15(2):498.

19. Patel H, Sharma P. Artificial intelligence in cachexia diagnosis. Front Oncol. 2022;12:945872.
20. Lerner L. Circulating biomarkers GDF-15 and activin A. J Cachexia Sarcopenia Muscle. 2023;14(2):875–85.
21. Chae H, Jeon D, Kim J, Lee J. Wearables in oncology cachexia. Sensors (Basel). 2022;22(20):7859.
22. Keane N, Ryan AM. Digital health in cachexia. Clin Nutr. 2023;42(2):223–32.
23. Cereda E, Caccialanza R, Crotti S, Brovia C. Immunonutrition in oncology. Nutrients. 2022;14(9):1921.
24. Hopkinson JB, Fenlon D. Psychosocial support in cachexia. Palliat Med. 2023;37(5):712–23.
25. Blauwhoff-Buskermolen S, Jager A. Precision medicine in cachexia. Support Care Cancer. 2023;31(2):1357–69.
26. Li X, Wang M, Shi X, Zeng L. CRISPR-Cas9 for myostatin inhibition. Mol Ther Nucleic Acids. 2023;32:235–45.
27. Zhang X. Gut microbiota and cachexia. J Cachexia Sarcopenia Muscle. 2023;14(3):1287–98.
28. Chen M, Yao Z, Liu F, Wei Y, Zang Y. Nanomedicine for cachexia. Adv Drug Deliv Rev. 2022;189:114514.
29. Kimura M. Multimodal interventions in cachexia. Support Care Cancer. 2023;31(8):4219–33.
30. Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754–62.
31. Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia. Clin Nutr. 2010;29(2):154–59.
32. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2021;7:171.
33. Shad A, Gupta R. Pediatric vs adult cachexia. Pediatr Blood Cancer. 2024;71(2):e30645.
34. Nayak MG, Rao R. Cachexia in low- and middle-income countries. Asia Pac J Clin Oncol. 2022;18(5):400–08.
35. Brown DJ. Trial design challenges. Cancers (Basel). 2023;15(14):3621.

